PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.
The consensus price target hints at a 261.4% upside potential for Pacific Biosciences (PACB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
With me today are Christian Henry, president and chief executive officer; and Susan Kim, chief financial officer. Before we begin, I would like to remind you that on today's call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, expectations, intentions, guidance, and others, including expectations with respect to collaborations, cash flow, and product and technology launches. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results.